Myopia progression can be slowed with multifocal and orthokeratology lenses

Ophthalmology Times EuropeOphthalmology Times Europe June 2021
Volume 17
Issue 05

Orthokeratology and multifocal contact lenses provide clinically meaningful reductions in progression of myopia, research shows, but some questions, such as the ideal treatment duration, remain unanswered.

Myopia progression can be slowed with multifocal and orthokeratology lenses

This article was reviewed by Dr Amy K. Hutchinson.

As myopia rates continue to soar to epidemic levels worldwide, research has found that the use of orthokeratology and multifocal contact lenses provide clinically meaningful reductions in progression of the refractive error. Ophthalmologist Dr Amy K. Hutchinson recently commented on this. “Both lens types are thought to have a similar mechanism of action to slow myopic progression, and that mechanism is to eliminate peripheral hyperopic defocus and induce peripheral myopic defocus,” she said.

Peripheral hyperopic defocus occurs when myopia is corrected by monovision glasses or contact lenses. The central light rays focus on the fovea and provide a clear image, but peripheral light rays focus behind the plane of the retina, which is thought to play a role in myopia progression, she explained.

Related: Genetics analysis may predict myopia in children

According to Dr Hutchinson, in support of this, clinical observations show a “significant reduction in myopia progression when bifocal glasses, multifocal contact lenses or overnight orthokeratology lenses are used to reduce the peripheral hyperopic defocus”. When measuring myopia progression, the result is expressed as the percentage of the changes in dioptric progression or axial lengthening between a treatment and control group; a 50% slowing is considered ideal and over 30% acceptable.

Multifocal contact lenses

The centre distance design is used most often in multifocal lenses, in which the central area of the lens focuses the image on the fovea. “The peripheral area has a more positive power resulting from either distinct concentric rings or a gradual progressive increase toward the periphery,” Dr Hutchinson explained. This design provides the wearer with clear central vision and both eliminates the peripheral hyperopic defocus and introduces peripheral myopic defocus, which decreases the stimulus for myopic progression associated with monovision glasses and contact lenses.

Related: Exploring possibilities of myopia prevention and control in the US

Currently, the MiSight multifocal contact lens by Cooper Vision is the only United States Food and Drug Administration-approved contact lens for myopia control. It has concentric peripheral rings that include a +2.00 D add. In a 3-year study, the lens slowed myopia progression in children (aged 8-12 years; refractive errors up to -4.0 D) by 59% and axial elongation by 52% compared with age-matched control children.

Other spherical and toric multifocal lenses are available for off-label use. Dr Hutchinson noted that evidence has suggested that higher add powers may result in better control of myopia progression. These lenses have been shown to slow myopia progression by -9.7–70% and slow axial elongation by 0–79%.


Orthokeratology lenses are worn overnight and temporarily reshape the cornea. “This technology uses a reverse-geometry rigid gas-permeable contact lens in which the base curve radius is flatter than the central corneal curvature, and the secondary curve is steeper than the base curve radius,” said Dr Hutchinson.

The central corneal flattening focuses the image on the fovea and eliminates the need for the patient to wear correction during the day. The lens steepens the mid-peripheral cornea and induces myopic defocus on the peripheral retina, thus controlling the myopia.

Related: AAO: Myopia progression slowed with orthokeratology, multifocal lenses

The lenses, which are most useful for patients with low to moderate myopia, have demonstrated a 30–80% slowing of axial elongation. Slowing of the dioptric progression is not usually reported because the lenses cause a temporary shift in the refractive shift. There is some evidence that these lenses might be useful to treat anisometropia as well.

In the US, orthokeratology lenses are approved for wear overnight but not for myopia control, whilst in Europe, the Menicon Bloom lens (Menicon) is CE-marked for the control of myopia progression, one version being for nightly use and a second type designed for daily use.

Related: Corneal crosslinking outcomes appear to justify its use in paediatrics

However, safety with overnight contact lens wear has been a pervasive concern. There has only been one large retrospective study to estimate the incidence of microbial keratitis associated with overnight orthokeratology lens wear.

Based on the upper confidence interval of this study, the expected incidence of microbial keratitis is no more than 50 per 10,000 patient years, or 1 in 200 years of wear. However, avoiding the use of tap water is recommended. Overall, despite the reported success with contact lens wear to slow myopia progression, questions remain unanswered, including the ideal time to begin treatment, recommended treatment duration and what the rate of rebound myopia is with discontinuation of contact lens wear.

Amy Hutchinson, MD
Dr Hutchinson is professor of ophthalmology and director of paediatric ophthalmology, Emory University School of Medicine, Atlanta, Georgia, US, and chief of ophthalmology at Children’s Healthcare of Atlanta. She has no financial interest in this subject matter.

Related Content: Cataract & Refractive | Paediatrics | Inflammation & Infection

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.